Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ribon Therapeutics

Request full access

Ribon Therapeutics is pioneering the discovery and development of monoPARP inhibitors

Cambridge, United StatesFounded 2015Biotech & Life Sciences

About Ribon Therapeutics

Ribon Therapeutics is a clinical stage biopharmaceutical company that specializes in the development of novel small molecules targeting stress support pathways in cancer and inflammation. The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, clinics, and other healthcare providers.

The company's business model revolves around its proprietary BEACON+ platform. This platform is designed to explore the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics. In simple terms, Ribon Therapeutics uses this platform to create new drugs that can target and disrupt the processes that cause cancer and inflammation.

One of the company's leading products is RBN-2397, a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7. This drug is being developed for the treatment of solid tumors. The company has recently started a Phase 1 clinical study with another product, RBN-3143, in patients with moderate-to-severe atopic dermatitis.

Ribon Therapeutics generates revenue through the sale of its developed drugs to healthcare providers. The company also potentially earns income from partnerships with other pharmaceutical companies, research grants, and licensing agreements.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Cambridge, United States
Employees
5
Open positions
None listed
Dealroom signal
69.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jan 2023 $25M $325M Pfizer ↗
DEBTDebt Apr 2022 $50M — K2 HealthVentures ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Ribon Therapeutics website traffic

Latest recorded traffic for Ribon Therapeutics is 110 monthly website visits, down 83.6% over the last three months. Ribon Therapeutics's team declined 16.7% over the past year.

Latest monthly visits110 3-month web change-83.6% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ribon Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Ribon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • The Column Group
  • Osage University Partners
  • Novartis Venture Fund
  • Celgene
  • Deerfield
  • U.S. Venture Partners
  • Takeda Ventures
  • Johnson & Johnson Innovation
  • Euclidean Capital

Series B and later7 investors entered at this stage

  • Abbvie Biotech Ventures
  • Monashee Investment Management
  • Bristol-Myers Squibb
  • Peregrine Ventures
  • Avego Bioscience Capital
  • K2 HealthVentures
  • Pfizer

Other known investors3 additional known investors

  • Harvard University
  • Massachusetts Institute of Technology
  • UT Southwestern
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ribon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ribon Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.